Alexandra D. Carides

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 770 citations

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

S. Poli-Bigelli, José Rodrigues-Pereira, Alexandra D. Carides et al. · Cancer · 2003 · 566 citations

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla et al. · New England Journal of Medicine · 1999 · 370 citations · Full text

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

Bernardo L. Rapoport, Karin Jordan, Judith A. Boice et al. · Supportive Care in Cancer · 2009 · 233 citations

Emetogenic Chemotherapies, Oncology, Chemotherapy-induced Nausea +9

Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone

José Rodrigues Pereira, Rick R. Reinhardt, Carlos Carracedo et al. · Journal of Clinical Oncology · 2001 · 221 citations